Cargando…

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma

Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone...

Descripción completa

Detalles Bibliográficos
Autores principales: Psilopatis, Iason, Pergaris, Alexandros, Giaginis, Constantinos, Theocharis, Stamatios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604582/
https://www.ncbi.nlm.nih.gov/pubmed/34804263
http://dx.doi.org/10.1155/2021/7850688
_version_ 1784601993815261184
author Psilopatis, Iason
Pergaris, Alexandros
Giaginis, Constantinos
Theocharis, Stamatios
author_facet Psilopatis, Iason
Pergaris, Alexandros
Giaginis, Constantinos
Theocharis, Stamatios
author_sort Psilopatis, Iason
collection PubMed
description Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone acetylation in many cell types, thereby inducing cell cycle arrest, differentiation, and apoptotic cell death. This review is aimed at determining the role of histone acetylation and examining the therapeutic potential of histone deacetylase inhibitors in endometrial cancer. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms histone deacetylase, histone deacetylase inhibitor, and endometrial cancer were employed, and we were able to identify fifty-two studies focused on endometrial carcinoma and published between 2001 and 2021. Deregulation of histone acetylation is involved in the tumorigenesis of both endometrial carcinoma histological types and accounts for high-grade, aggressive carcinomas with worse prognosis and decreased overall survival. Histone deacetylase inhibitors inhibit tumor growth, enhance the transcription of silenced physiologic genes, and induce cell cycle arrest and apoptosis in endometrial carcinoma cells both in vitro and in vivo. The combination of histone deacetylase inhibitors with traditional chemotherapeutic agents shows synergistic cytotoxic effects in endometrial carcinoma cells. Histone acetylation plays an important role in endometrial carcinoma development and progression. Histone deacetylase inhibitors show potent antitumor effects in various endometrial cancer cell lines as well as tumor xenograft models. Additional clinical trials are however needed to verify the clinical utility and safety of these promising therapeutic agents in the treatment of patients with endometrial cancer.
format Online
Article
Text
id pubmed-8604582
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86045822021-11-20 Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma Psilopatis, Iason Pergaris, Alexandros Giaginis, Constantinos Theocharis, Stamatios Dis Markers Review Article Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone acetylation in many cell types, thereby inducing cell cycle arrest, differentiation, and apoptotic cell death. This review is aimed at determining the role of histone acetylation and examining the therapeutic potential of histone deacetylase inhibitors in endometrial cancer. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms histone deacetylase, histone deacetylase inhibitor, and endometrial cancer were employed, and we were able to identify fifty-two studies focused on endometrial carcinoma and published between 2001 and 2021. Deregulation of histone acetylation is involved in the tumorigenesis of both endometrial carcinoma histological types and accounts for high-grade, aggressive carcinomas with worse prognosis and decreased overall survival. Histone deacetylase inhibitors inhibit tumor growth, enhance the transcription of silenced physiologic genes, and induce cell cycle arrest and apoptosis in endometrial carcinoma cells both in vitro and in vivo. The combination of histone deacetylase inhibitors with traditional chemotherapeutic agents shows synergistic cytotoxic effects in endometrial carcinoma cells. Histone acetylation plays an important role in endometrial carcinoma development and progression. Histone deacetylase inhibitors show potent antitumor effects in various endometrial cancer cell lines as well as tumor xenograft models. Additional clinical trials are however needed to verify the clinical utility and safety of these promising therapeutic agents in the treatment of patients with endometrial cancer. Hindawi 2021-11-12 /pmc/articles/PMC8604582/ /pubmed/34804263 http://dx.doi.org/10.1155/2021/7850688 Text en Copyright © 2021 Iason Psilopatis et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Psilopatis, Iason
Pergaris, Alexandros
Giaginis, Constantinos
Theocharis, Stamatios
Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_full Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_fullStr Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_full_unstemmed Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_short Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_sort histone deacetylase inhibitors: a promising therapeutic alternative for endometrial carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604582/
https://www.ncbi.nlm.nih.gov/pubmed/34804263
http://dx.doi.org/10.1155/2021/7850688
work_keys_str_mv AT psilopatisiason histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma
AT pergarisalexandros histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma
AT giaginisconstantinos histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma
AT theocharisstamatios histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma